224 related articles for article (PubMed ID: 25740311)
1. Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain.
Richards MW; O'Regan L; Roth D; Montgomery JM; Straube A; Fry AM; Bayliss R
Biochem J; 2015 May; 467(3):529-36. PubMed ID: 25740311
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain.
Richards MW; Law EW; Rennalls LP; Busacca S; O'Regan L; Fry AM; Fennell DA; Bayliss R
Proc Natl Acad Sci U S A; 2014 Apr; 111(14):5195-200. PubMed ID: 24706829
[TBL] [Abstract][Full Text] [Related]
3. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Bayliss R; Choi J; Fennell DA; Fry AM; Richards MW
Cell Mol Life Sci; 2016 Mar; 73(6):1209-24. PubMed ID: 26755435
[TBL] [Abstract][Full Text] [Related]
5. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J
BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412
[TBL] [Abstract][Full Text] [Related]
6. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
7. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
[TBL] [Abstract][Full Text] [Related]
8. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
10. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
Mano H
Cancer Sci; 2008 Dec; 99(12):2349-55. PubMed ID: 19032370
[TBL] [Abstract][Full Text] [Related]
11. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
[TBL] [Abstract][Full Text] [Related]
12. EML4-ALK fusions: propelling cancer but creating exploitable chaperone dependence.
Workman P; van Montfort R
Cancer Discov; 2014 Jun; 4(6):642-5. PubMed ID: 24891363
[TBL] [Abstract][Full Text] [Related]
13. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.
Sanders HR; Li HR; Bruey JM; Scheerle JA; Meloni-Ehrig AM; Kelly JC; Novick C; Albitar M
Cancer Genet; 2011 Jan; 204(1):45-52. PubMed ID: 21356191
[TBL] [Abstract][Full Text] [Related]
14. EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.
O'Regan L; Barone G; Adib R; Woo CG; Jeong HJ; Richardson EL; Richards MW; Muller PAJ; Collis SJ; Fennell DA; Choi J; Bayliss R; Fry AM
J Cell Sci; 2020 May; 133(9):. PubMed ID: 32184261
[TBL] [Abstract][Full Text] [Related]
15. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
[TBL] [Abstract][Full Text] [Related]
16. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
[TBL] [Abstract][Full Text] [Related]
17. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract][Full Text] [Related]
18. EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity.
Lucken K; O'Regan L; Choi J; Sampson J; Pashley SL; Bayliss R; Khan S; Fry AM
Mol Cancer Res; 2022 Jun; 20(6):854-866. PubMed ID: 35656694
[TBL] [Abstract][Full Text] [Related]
19. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
20. Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.
Cheon SY; Kwon S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
